Bladder Cancer

Elizabeth Plimack, MD, MS, chief of the division of genitourinary medical oncology at Fox Chase Cancer Center, has been appointed the center’s deputy director.

Among individuals with certain cancers, treatment with radiotherapy was associated with poorer long-term CV-specific survival compared with those who did not undergo radiotherapy, researchers reported.

SAN FRANCISCO — Addressing disparities in genitourinary cancers requires more research on changing risk factors and immediate actions aimed at prevention, Karen E. Knudsen, PhD, MBA, said during ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — Neoadjuvant treatment with enfortumab vedotin demonstrated promising activity among cisplatin-ineligible patients with muscle-invasive bladder cancer, according to study results presented at ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — Lenvatinib plus pembrolizumab did not demonstrate a positive benefit-risk ratio compared with pembrolizumab and placebo as first-line therapy for certain patients with advanced urothelial carcinoma, study results showed.

Shilpa Gupta, MD, has been appointed director of genitourinary medical oncology at Taussig Cancer Institute and co-leader of the genitourinary oncology program at Cleveland Clinic.

Transurethral resection of bladder tumor plus systemic therapy induced clinical complete response among a large subset of patients with muscle-invasive bladder cancer, according to phase 2 study results.

Genentech voluntarily withdrew atezolizumab’s indication in the United States for patients with platinum-treated metastatic urothelial carcinoma.

Any aspirin use and aspirin use at least three times per week appeared associated with improvements in survival outcomes among older adults with bladder and breast cancers, according to study results published in JAMA Network Open.

AstraZeneca voluntarily withdrew durvalumab’s indication for treatment of adults with locally advanced or metastatic bladder cancer.